JILLIAN MCCLINTOCK
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner HERMITAGE, TN NPI 1992306609
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner TN Janssen Biotech, Inc. All categories
General Payments — all program years on this page
$2,765.95
- Category: General Payments
- Program years: PY2021–2024
- Record count: 81
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,540.74 across 53 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,380.43 | 51 |
| Education | $160.31 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $256.49 | 7 |
| Regeneron Healthcare Solutions, Inc. | $135.46 | 8 |
| Kite Pharma, Inc. | $116.34 | 1 |
| Lilly USA, LLC | $107.08 | 2 |
| AVEO Pharmaceuticals, Inc. | $105.83 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $100.91 | 3 |
| Celgene Corporation | $65.94 | 3 |
| Acerta Pharma LLC | $62.50 | 3 |
| Exelixis Inc. | $49.96 | 2 |
| Merck Sharp & Dohme Corporation | $49.50 | 2 |
| Blueprint Medicines Corporation | $42.03 | 1 |
| BeiGene USA, Inc. | $39.31 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $37.98 | 2 |
| GENZYME CORPORATION | $35.31 | 2 |
| Ipsen Biopharmaceuticals, Inc | $34.09 | 1 |
| EISAI INC. | $30.31 | 1 |
| Kyowa Kirin, Inc. | $29.65 | 1 |
| Verity Pharmaceuticals Inc. | $27.94 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $26.78 | 1 |
| EMD Serono, Inc. | $26.02 | 1 |
| Alnylam Pharmaceuticals Inc. | $24.99 | 1 |
| Genmab U.S., Inc. | $24.74 | 1 |
| Incyte Corporation | $23.60 | 1 |
| ABBVIE INC. | $23.20 | 1 |
| JAZZ PHARMACEUTICALS INC. | $22.67 | 1 |
| Mirati Therapeutics, Inc. | $21.89 | 1 |
| TAIHO ONCOLOGY, INC. | $20.22 | 1 |
By program year
Records — PY2024 (53)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.